Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Movement Disorders

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/mds.870080411PMID 8232357
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic use of type F botulinum toxin.

  1992cited by this paper
• Writer's cramp: Treatment with botulinum toxin injections

  1991cited by this paper
• Double‐blind controlled study of botulinum toxin in adductor spasmodic dysphonia

  1991cited by this paper
• A double blind trial of botulinum toxin "A" in torticollis, with one year follow up.

  1991cited by this paper
• Treatment of idiopathic spasmodic torticollis with botulinum toxin a: A double‐blind study on twenty‐three patients

  1991cited by this paper
• Double‐blind, placebo‐controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis

  1990cited by this paper
• Botulinum toxin treatment in spasmodic torticollis.

  1990cited by this paper
• Botulinum Toxin Injection for the Treatment of Oromandibular Dystonia

  1989cited by this paper
• Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (ABCDE) toxoid

  1989cited by this paper
• Treatment of focal dystonias of the hand with botulinum toxin injections.

  1989cited by this paper
• Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis

  1989cited by this paper
• Laboratory Diagnosis of Infectious Diseases Principles and Practice

  1988cited by this paper
• HTLV‐I, Adult T‐Cell leukemia, and tropical spastic paraparesis

  1988cited by this paper
• Botulinum toxin treatment of spasmodic torticollis.

  1988cited by this paper
• Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay

  1988cited by this paper
• Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm

  1987cited by this paper
• Botulinum A toxin for cranial‐cervical dystonia

  1987cited by this paper
• Double-blind study of botulinum toxin in spasmodic torticollis.

  1986cited by this paper
• Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction.

  1985cited by this paper
• Statistical testing in dermatoglyphic studies.

  1985cited by this paper
• Purification and properties of Clostridium botulinum type F toxin.

  1975cited by this paper
• PHENOTHIAZINE DYSKINESIA AFTER LEUCOTOMY.

  1964cited by this paper
• Botulism

  1949cited by this paper
• A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS

  1938cited by this paper

• Developing Botulinum Toxin Drugs: Unexpected Challenges.

  2026cites this paper
• Lessons about Botulinum Toxin A Therapy from Cervical Dystonia Patients Drawing the Course of Disease: A Pilot Study

  2023cites this paper
• Transient Receptor Potential Channels and Botulinum Neurotoxins in Chronic Pain

  2021cites this paper
• Novel Native and Engineered Botulinum Neurotoxins.

  2020cites this paper
• Clinical duration of action of different botulinum toxin types in humans.

  2020cites this paper
• The Expanding Therapeutic Utility of Botulinum Neurotoxins

  2018cites this paper
• Immunological aspects of botulinum toxin therapy

  2017cites this paper
• Substrate cleavage and duration of action of botulinum neurotoxin type FA (“H, HA”)

  2017cites this paper
• Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.

  2016cites this paper
• Botulinum toxin type B for cervical dystonia.

  2016cites this paper
• Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.

  2016cites this paper
• Clostridial neurotoxins: from the cellular and molecular mode of action to their therapeutic use

  2015cites this paper
• Current Status and Future Directions of Botulinum Neurotoxins for Targeting Pain Processing

  2015cites this paper
• Treatment of cervical dystonia

  2013cites this paper
• Botulism and Tetanus

  2013cites this paper
• Botulinum toxins: mechanisms of action, antinociception and clinical applications.

  2013cites this paper
• Advances in the use of botulinum neurotoxins in facial esthetics

  2012cites this paper
• Botulinum Toxin for the Treatment of Movement Disorders

  2012cites this paper
• Flu-like symptoms following botulinum toxin therapy.

  2011cites this paper
• Clostridium botulinum und seine Toxine: Krankheitserreger und potentielle Biowaffe?

  2011cites this paper
• Botulinum toxin therapy for cervical dystonia: review of the clinical evidence and ongoing studies

  2011cites this paper
• 2 – Aspectos generales de la aplicación de la toxina botulínica

  2010cites this paper
• Temporal characteristics of botulinum neurotoxin therapy

  2010cites this paper
• Search USE OF BOTULINUM TOXIN-A IN PAIN ASSOCIATED WITH NEUROMUSCULAR DISORDERS July 2001 Executive Summary

  2009cites this paper
• Chapter 6 – Biology and Clinical Pharmacology of Botulinum Neurotoxin Type C and Other Non-A/Non-B Botulinum Neurotoxins

  2009cites this paper
• Nachweis von Botulinum-Toxin-Antikörper

  2008cites this paper
• Botulinum toxin type A in the treatment of patients with cervical dystonia

  2008cites this paper
• [Proof of botulinum toxin antibodies with the Extensor Digitorum Brevis Test].

  2008cites this paper
• How do the Botulinum Neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action

  2008cites this paper
• Upper Motor Neurone Syndrome and Spasticity: Spasticity and botulinum toxin

  2008cites this paper
• Myriad Uses of Botulinum Toxin 31 6 Myriad Uses of Botulinum Toxin BP

  2007cites this paper
• Treatment of dystonia

  2006cites this paper
• Clinical Use of Non-A Botulinum Toxins: Botulinum Toxin Type C and Botulinum Toxin Type F

  2006cites this paper
• Myobloc® for the Treatment of Benign Essential Blepharospasm in Patients Refractory to Botox®

  2006cites this paper
• Clinical use of non-a botulinum toxins: Botulinum toxin type C and botulinum toxin type F

  2006cites this paper
• Botulinum Toxin: From Molecule to Clinic

  2006cites this paper
• The safety and tolerability of botulinum toxins for the treatment of cervical dystonia

  2005cites this paper
• Botulinum Toxins: Transformation of a Toxin into a Treatment

  2005cites this paper
• Different types of botulinum toxin in humans

  2004cites this paper
• Dystone Störungen und psychische Beeinträchtigung am Beispiel der zervikalen Dystonie

  2004cites this paper
• Treatment of cervical dystonia with botulinum toxin

  2004cites this paper
• [First use of botulinum toxin type B in ENT patients with secondary therapy failure of botulinum toxin type A].

  2004cites this paper
• Development of resistance to botulinum toxin type A in patients with torticollis

  2004cites this paper
• Botulinum toxins in neurological disease

  2004cites this paper
• Erste Anwendung bei HNO-Patienten mit sekundärem Therapieversagen von Botulinumtoxin Typ A

  2004cites this paper
• Botulinum toxin: a successful therapeutic protein.

  2004cites this paper
• Chapter 78 – Dyskinesias

  2003cites this paper
• [Mode of action of botulinum neurotoxin: pathological, cellular and molecular aspect].

  2003cites this paper
• Botulinum toxin therapy in pain management.

  2003cites this paper
• Erste Anwendung von Botulinumtoxin Typ B bei HNO-Patienten mit sekundärem Therapieversagen von Botulinumtoxin Typ A

  2003cites this paper
• Injection of Botulinum Toxin Type B for the Treatment of Otolaryngology Patients With Secondary Treatment Failure of Botulinum Toxin Type A

  2003cites this paper
• Le mode d’action des neurotoxines botuliques : aspects pathologiques, cellulaires et moléculaires

  2003cites this paper
• Botulinum toxin type A (BOTOX) for treatment of migraine.

  2002cites this paper
• Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia

  2002cites this paper
• Comparison of neuromuscular blockade and recovery with botulinum toxins A and F

  2002cites this paper
• [Botulinum toxin--the dose controls the poison. A historical sketch].

  2002cites this paper
• Botulinumtoxin – Die Dosis macht das GiftEin historischer Abriss

  2002cites this paper
• Therapeutic Use of Botulinum Toxins: Background and History

  2002cites this paper
• Extensor digitorum brevis test and resistance to botulinum toxin type A

  2002cites this paper
• Muscle paralysis produced by botulinum toxin type A injection in treated torticollis patients compared with toxin naive individuals

  2001cites this paper
• Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects

  2001cites this paper
• Botulinum toxin type B (Myobloc™, NeuroBloc™): a new choice in cervical dystonia

  2001cites this paper
• Magnetic resonance imaging and computed tomographic findings after temporal lobe injury.

  2001cites this paper
• The Botulinum Toxins in the Treatment of Cervical Dystonia

  2001cites this paper
• Botulinum toxin type A (BOTOX) for treatment of migraine.

  2001cites this paper
• Treatment of Frey syndrome with botulinum toxin type F.

  2001cites this paper
• Botulinum toxin type B: a new injectable treatment for cervical dystonia

  2001cites this paper
• [Botulinum toxin A for the treatment of headache disorders and pericranial pain syndromes].

  2001cites this paper
• Botulinum-Toxin A in der Therapie von Kopfschmerzerkrankungen und perikranialen Schmerzsyndromen

  2001cites this paper
• Botulinum toxin and spasticity

  2000cites this paper
• Cerebral dysfunction and psychotic symptoms in Alzheimer’s disease

  2000cites this paper
• The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials.

  2000cites this paper
• Cerebral dysfunction and psychotic symptoms in Alzheimer’s disease

  2000cites this paper
• Cerebral dysfunction and psychotic symptoms in Alzheimer’s disease

  2000cites this paper
• Effect of prolonged neck muscle vibration on lateral head tilt in severe spasmodic torticollis

  2000cites this paper
• The effects of tetanus toxin on the orbicularis oculi muscle.

  2000cites this paper
• Pharmacotherapy with Botulinum Toxin: Harnessing Nature's Most Potent Neurotoxin

  2000cites this paper
• Surgery for Spasmodic Torticollis

  2000cites this paper
• The current use of botulinum toxin.

  2000cites this paper
• Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.

  1999cites this paper
• Botulinum toxin in motor disorders.

  1999cites this paper
• Retention of cleaved synaptosome-associated protein of 25 kDa (SNAP-25) in neuromuscular junctions: a new hypothesis to explain persistence of botulinum A poisoning.

  1999cites this paper
• Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A

  1998cites this paper
• Secondary dystonias

  1998cites this paper
• Mouse bioassay versus Western blot assay for botulinurn toxin antibodies Correlation with clinical response

  1998cites this paper
• Doxorubicin chemomyectomy as a treatment for cervical dystonia: Histological assessment after direct injection into the sternocleidomastoid muscle

  1998cites this paper
• Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections

  1998cites this paper
• Has botulinum toxin type A a place in the treatment of spasticity in spinal cord injury patients?

  1998cites this paper
• Botulinum toxin type F for treatment of dystonia

  1998cites this paper
• [Current indications of botulinum toxin treatment].

  1997cites this paper
• Human Tetanus and Human Botulism

  1997cites this paper
• The EBD test--a clinical test for the detection of antibodies to botulinum toxin type A.

  1997cites this paper
• Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology

  1997cites this paper
• Reconstituted Botulinum Toxin Type A Does Not Lose Potency in Humans If It Is Refrozen or Refrigerated for 2 Weeks Before Use

  1997cites this paper
• Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human.

  1997cites this paper
• The EDB Test—A clinical test for the detection of antibodies to botulinum toxin type A

  1997cites this paper
• The therapeutic use of botulinum toxin.

  1997cites this paper
• Human response to botulinum toxin injection: Type B compared with type A

  1997cites this paper
• Botulinum toxin: Historical perspective and potential new indications

  1997cites this paper
• Sensitive assay for measurement of antibodies to Clostridium botulinum neurotoxins A, B, and E: use of hapten-labeled-antibody elution to isolate specific complexes

  1997cites this paper